FDA approves Blenrep for relapsed or refractory multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved GSK‘s Blenrep (belantamab mafodotin) for adults with relapsed or refractory multiple myeloma. The approval…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Advocates urge action after NICE rejects Voranigo for England’s NHS
In a setback for brain tumor patients, England’s National Health Service (NHS) has been advised not to routinely cover the new cancer therapy Voranigo…
Nearly half of endometrial cancer patients respond to Rina-S in trial
Nearly half of women with hard-to-treat endometrial cancer responded to the investigational therapy Rina-S (rinatabart sesutecan) in a Phase 2 clinical trial, according to new…
Tecvayli-Darzalex Faspro combo extends survival in myeloma trial
People with hard-to-treat myeloma given a combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) — both approved cancer therapies from…
Treatment extends pancreatic cancer survival to 2 years: Trial data
Six of 10 pancreatic cancer patients treated with the investigational drug certepetide along with chemotherapy prior to surgery were alive two years later, according…
New treatment leads to longer survival for glioblastoma patients
In a small clinical trial involving individuals with recurrent glioblastoma — a highly aggressive form of glioma — patients who received a single injection…
Results expected soon on burixafor for myeloma stem cell transplants
Results from a clinical trial testing Exicure‘s therapy candidate burixafor (GPC-100) in stem cell transplants for people with myeloma are expected soon — and the developer…
Kernal Bio awarded up to $48M to develop blood cancer treatments
The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $48 million to Kernal Bio to support the development of more efficient,…
All main goals hit in trial testing AlphaMedix for pancreatic cancer
A Phase 2 clinical trial testing Sanofi‘s therapy candidate AlphaMedix (212Pb-DOTAMTATE) in people with a certain type of pancreatic cancer has hit all its…
FDA grants orphan drug designation to glioblastoma treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
